Biopharmaceutical company Takeda (TSE:4502) (NYSE:TAK) announced on Monday that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] has been approved in Europe as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilisation with intravenous immunoglobulin therapy (IVIG).

HyQvia offers a flexible treatment option, allowing patients to infuse up to once monthly, either at home or in-office. The first and only facilitated subcutaneous immunoglobulin (fSCIG) for CIDP, HyQvia aids in dispersion and absorption of large immunoglobulin volumes in the subcutaneous space between the skin and the muscle.

The European Commission's approval was based on Phase 3 data showing a significant reduction in CIDP relapse rate with HyQvia versus placebo.